

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LANSEN PHARMACEUTICAL HOLDINGS LIMITED

朗生醫藥控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 503)

**CHANGE OF COMPANY SECRETARY,
CHIEF FINANCIAL OFFICER AND
AUTHORIZED REPRESENTATIVE**

The Board announces that with effect from 16 September 2015:

- (1) Mr. Mui Chi Hung resigned as Company Secretary, Chief Financial Officer and Authorized Representative of the Company; and
- (2) Mr. Leung Tsz Chun has been appointed as Company Secretary and Authorized Representative of the Company.

The board of directors (the “**Board**”) of Lanssen Pharmaceutical Holdings Limited (the “**Company**”) announces that Mr. Mui Chi Hung (“**Mr. Mui**”) will resign as Company Secretary, Chief Financial Officer and one of the authorized representatives (for the purpose of Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Part XI of the Hong Kong Companies Ordinance) of the Company, with effect from 16 September 2015, as he has to pursue his other career opportunities. Mr. Mui confirmed that he has no disagreement with the Board and there is no other matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

As at the date of this announcement, the Board has identified a suitable candidate to fill the vacancy of Chief Financial Officer and would endeavour to expedite the appointment process, which is expected to be made in mid-September of 2015. Further announcement will be made in relation to such appointment as and where appropriate.

The Board is pleased to announce that Mr. Leung Tsz Chun (“**Mr. Leung**”), the Finance Manager of the Company, has been appointed as Company Secretary and authorized representative (for the purpose of Rule 3.05 of the Listing Rules and Part XI of the Hong Kong Companies Ordinance) of the Company, with effect from 16 September 2015. Mr. Leung, aged 29, has over 7 years of experience in audit, finance and accounting. Prior to joining the Company in 2014, Mr. Leung worked in KPMG, Hong Kong for six years, last position as Audit Manager. Mr. Leung obtained his Bachelor of Science degree in Biochemistry from Hong Kong University of Science and Technology in 2008. Mr. Leung is a member of Hong Kong Institute of Certified Public Accountants.

The Board takes this opportunity to thank Mr. Mui for his valuable contribution during his tenure of services with the Company and wish him all the best in his new career pursuit.

By Order of the Board
Lansen Pharmaceutical Holdings Limited
Stephen Burnau Hunt
Chairman

Hong Kong, 4 September 2015

As at the date of this announcement, the executive Director is Mr. Liu Bang Min; the non-executive Directors are Mr. Stephen Burnau Hunt, Mr. Lee Jin Yi, Ms. Yip Pui Ling, Rebecca, Mr. Tang Jun and Ms. Tao Fang Fang; the independent non-executive Directors are Mr. Chan Kee Huen, Michael, Mr. Tang Chiu Ping, Raymond and Mr. Fritz Heinrich Horlacher.